Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 30 04 2018
accepted: 30 09 2018
pubmed: 9 11 2018
medline: 9 4 2020
entrez: 9 11 2018
Statut: ppublish

Résumé

Adult IDH-wildtype astrocytomas with TERT promoter mutations (TERTp) are associated with a poor prognosis. To analyze the radiological presentation and natural history of adult IDH-wildtype astrocytomas with TERTp. We retrospectively reviewed the characteristics of 40 IDH-wildtype TERTp-mutant astrocytomas (grade II n = 19, grade III n = 21) and compared them to those of 114 IDH-mutant lower grade gliomas (LGG), of 92 IDH-wildtype TERTp-mutant glioblastomas, and of 15 IDH-wildtype TERTp-wildtype astrocytomas. Most cases of IDH-wildtype TERTp-mutant astrocytomas occurred in patients aged >50 yr (88%) and presented as infiltrative lesions without contrast enhancement (73%) that were localized in the temporal and/or insular lobes (37.5%) or corresponded to a gliomatosis cerebri (43%). Thalamic involvement (33%) and extension to the brainstem (27%) were frequently observed, as was gyriform infiltration (33%). This radiological presentation was different from that of IDH-mutant LGG, IDH-wildtype TERTp-mutant glioblastomas, and IDH-wildtype TERTp-wildtype astrocytomas. Tumor evolution before treatment initiation was assessable in 17 cases. Ten cases demonstrated a rapid growth characterized by the apparition of a ring-like contrast enhancement and/or a median velocity of diametric expansion (VDE) ≥8 mm/yr but 7 cases displayed a slow growth (VDE <8 mm/yr) that could last several years before anaplastic transformation. Median overall survival of IDH-wildtype TERTp-mutant astrocytomas was 27 mo. IDH-wildtype TERTp-mutant astrocytomas typically present as nonenhancing temporo-insular infiltrative lesions or as gliomatosis cerebri in patients aged >50 yr. In the absence of treatment, although rapid tumor growth is frequent, an initial falsely reassuring, slow growth can be observed.

Sections du résumé

BACKGROUND
Adult IDH-wildtype astrocytomas with TERT promoter mutations (TERTp) are associated with a poor prognosis.
OBJECTIVE
To analyze the radiological presentation and natural history of adult IDH-wildtype astrocytomas with TERTp.
METHODS
We retrospectively reviewed the characteristics of 40 IDH-wildtype TERTp-mutant astrocytomas (grade II n = 19, grade III n = 21) and compared them to those of 114 IDH-mutant lower grade gliomas (LGG), of 92 IDH-wildtype TERTp-mutant glioblastomas, and of 15 IDH-wildtype TERTp-wildtype astrocytomas.
RESULTS
Most cases of IDH-wildtype TERTp-mutant astrocytomas occurred in patients aged >50 yr (88%) and presented as infiltrative lesions without contrast enhancement (73%) that were localized in the temporal and/or insular lobes (37.5%) or corresponded to a gliomatosis cerebri (43%). Thalamic involvement (33%) and extension to the brainstem (27%) were frequently observed, as was gyriform infiltration (33%). This radiological presentation was different from that of IDH-mutant LGG, IDH-wildtype TERTp-mutant glioblastomas, and IDH-wildtype TERTp-wildtype astrocytomas. Tumor evolution before treatment initiation was assessable in 17 cases. Ten cases demonstrated a rapid growth characterized by the apparition of a ring-like contrast enhancement and/or a median velocity of diametric expansion (VDE) ≥8 mm/yr but 7 cases displayed a slow growth (VDE <8 mm/yr) that could last several years before anaplastic transformation. Median overall survival of IDH-wildtype TERTp-mutant astrocytomas was 27 mo.
CONCLUSION
IDH-wildtype TERTp-mutant astrocytomas typically present as nonenhancing temporo-insular infiltrative lesions or as gliomatosis cerebri in patients aged >50 yr. In the absence of treatment, although rapid tumor growth is frequent, an initial falsely reassuring, slow growth can be observed.

Identifiants

pubmed: 30407589
pii: 5165251
doi: 10.1093/neuros/nyy513
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41
TERT protein, human EC 2.7.7.49
Telomerase EC 2.7.7.49

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

E448-E456

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 by the Congress of Neurological Surgeons.

Auteurs

Cristina Izquierdo (C)

Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuro-Oncologie, Lyon, France.
Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-ICO L'Hospitalet-IDIBELL, l'Hospitalet de Llo-bregat, Barcelona, Spain.

Marc Barritault (M)

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'anatomopathologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.

Delphine Poncet (D)

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'anatomopathologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.

Stéphanie Cartalat (S)

Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuro-Oncologie, Lyon, France.

Bastien Joubert (B)

Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuro-Oncologie, Lyon, France.

Jordi Bruna (J)

Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-ICO L'Hospitalet-IDIBELL, l'Hospitalet de Llo-bregat, Barcelona, Spain.

Emmanuel Jouanneau (E)

Université Claude Bernard Lyon 1, Lyon, France.
Hospices Civils de Lyon, Groupement Hospitalier Est, Service de Neurochirurgie B, Lyon, France.
Signaling, Metabolism and Tumor Progression, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.

Jacques Guyotat (J)

Hospices Civils de Lyon, Groupement Hospitalier Est, Service de Neurochirurgie D, Lyon, France.

Alexandre Vasiljevic (A)

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'anatomopathologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.

Tanguy Fenouil (T)

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'anatomopathologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.

Yves Berthezène (Y)

Université Claude Bernard Lyon 1, Lyon, France.
Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuroradiologie, Lyon, France.

Jérôme Honnorat (J)

Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuro-Oncologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France.

David Meyronet (D)

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'anatomopathologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.

François Ducray (F)

Hospices Civils de Lyon, Groupe Hos-pitalier Est, Service de Neuro-Oncologie, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH